Chemours Balance Sheet Health
Financial Health criteria checks 1/6
Chemours has a total shareholder equity of $239.0M and total debt of $4.1B, which brings its debt-to-equity ratio to 1717.2%. Its total assets and total liabilities are $7.5B and $7.2B respectively. Chemours's EBIT is $351.0M making its interest coverage ratio 1.3. It has cash and short-term investments of $502.0M.
Key information
1,717.15%
Debt to equity ratio
US$4.10b
Debt
| Interest coverage ratio | 1.3x |
| Cash | US$502.00m |
| Equity | US$239.00m |
| Total liabilities | US$7.25b |
| Total assets | US$7.49b |
Recent financial health updates
Chemours (NYSE:CC) Has No Shortage Of Debt
Jun 29
Chemours (NYSE:CC) Seems To Be Using A Lot Of Debt
Jan 24Recent updates
Chemours: Getting In Before The Upside And Before Q3
Oct 28The Chemours Company (NYSE:CC) Held Back By Insufficient Growth Even After Shares Climb 33%
Sep 03Is It Time To Consider Buying The Chemours Company (NYSE:CC)?
Jul 26The Chemours Company's (NYSE:CC) Price Is Right But Growth Is Lacking After Shares Rocket 30%
Jul 04Chemours (NYSE:CC) Has No Shortage Of Debt
Jun 29We Like The Quality Of Chemours' (NYSE:CC) Earnings
May 14Is There An Opportunity With The Chemours Company's (NYSE:CC) 48% Undervaluation?
Apr 25What Is The Chemours Company's (NYSE:CC) Share Price Doing?
Mar 19It's Down 27% But The Chemours Company (NYSE:CC) Could Be Riskier Than It Looks
Mar 04Chemours (NYSE:CC) Seems To Be Using A Lot Of Debt
Jan 24Are Investors Undervaluing The Chemours Company (NYSE:CC) By 50%?
Jan 08Not Many Are Piling Into The Chemours Company (NYSE:CC) Just Yet
Dec 05Chemours: Hasn't Been A Great Year, But The Long-Term Prospects Look Bright
Nov 21Chemours' (NYSE:CC) Earnings Offer More Than Meets The Eye
Nov 12Is It Too Late To Consider Buying The Chemours Company (NYSE:CC)?
Sep 25
Shane Hostetter's CFO Role And TT Transformation Plan Promise Operational Excellence And Growth Surge
Operational efficiency improvements signaled by new CFO leadership and achievement in cost savings point towards better net margins and operating income.Chemours: We're Back Down To Trough And A 'BUY'
Sep 01Chemours: Upside After Irregularities, Good 2024-2026E
Jun 11The Chemours Company's (NYSE:CC) Low P/S No Reason For Excitement
May 30Financial Position Analysis
Short Term Liabilities: CC's short term assets ($3.1B) exceed its short term liabilities ($1.9B).
Long Term Liabilities: CC's short term assets ($3.1B) do not cover its long term liabilities ($5.4B).
Debt to Equity History and Analysis
Debt Level: CC's net debt to equity ratio (1507.1%) is considered high.
Reducing Debt: CC's debt to equity ratio has increased from 650.8% to 1717.2% over the past 5 years.
Debt Coverage: CC's debt is not well covered by operating cash flow (6.3%).
Interest Coverage: CC's interest payments on its debt are not well covered by EBIT (1.3x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/02 08:20 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
The Chemours Company is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Alembic Global Advisors |
| David Coleman | Argus Research Company |
| Michael Leithead | Barclays |